TEW 7197

Drug Profile

TEW 7197

Alternative Names: EW-7197; TEW7197

Latest Information Update: 23 Oct 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Ewha Womans University
  • Developer MedPacto; National OncoVenture
  • Class Aniline compounds; Antineoplastics; Fluorine compounds; Imidazoles; Pyridines; Small molecules; Triazoles
  • Mechanism of Action Transforming growth factor beta type I receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 10 May 2017 Case Comprehensive Cancer Center plans a phase I trial for Multiple myeloma (Relapsed, Refractory metastatic disease, Combination therapy) in USA (NCT03143985)
  • 10 Mar 2017 MedPacto plans a phase I/II trial for Myelodysplastic syndromes (Monotherapy) in USA (NCT03074006)
  • 21 Oct 2014 The Safety Monitoring Committee recommends to proceed with the dose-escalation to the next level following a safety review of the first cohort in a phase I trial in Solid tumours in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top